^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    lenalidomide

    i
    Other names: IMiD3, CDC 5013, CC-5013, CDC-501, CDC-5013, IMiD-1, IMiD-3, ENMD-0997, CC 5013, CDC 5013, ENMD 0997
    Company:
    Generic mfg.
    Drug class:
    TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor
    Related drugs:
    2d
    SIDNEY: A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=80, Recruiting, Enterome | N=60 --> 80 | Trial completion date: May 2032 --> May 2034 | Trial primary completion date: May 2026 --> May 2029
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • lenalidomide • EO2463
    3d
    A Prospective, Single-Arm, Multicenter Study on the Efficacy and Safety of Lisaftoclax Combined with Rituximab and Lenalidomide Regimen in the Treatment of Previously Untreated Elderly Patients with Mantle Cell Lymphoma (ChiCTR2500115112)
    P=N/A, N=40, Not yet recruiting, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University; Jiangsu Province Hospital, The First Affiliated Hospital of Na
    New trial
    |
    Rituxan (rituximab) • lenalidomide • lisaftoclax (APG-2575)
    3d
    A multicenter prospective randomized controlled study of quadruplet regimen in newly diagnosed transplant-ineligible high-risk multiple myeloma patients (ChiCTR2600116772)
    P4, N=117, Not yet recruiting, Peking Union Medical College Hospital; Peking Union Medical College Hospital
    New P4 trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    lenalidomide • bortezomib • Sarclisa (isatuximab-irfc)
    3d
    Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM (ChiCTR2600117745)
    P3, N=1216, Recruiting, Peking University People's Hospital; Peking University People's Hospital
    New P3 trial
    |
    lenalidomide • iberdomide (CC-220)
    3d
    Rituximab, Lenalidomide, and Orelabrutinib Combination Regimen in the Treatment of marginal zone cell lymphoma: a Prospective, Single-Arm, Phase II Clinical Study (ChiCTR2500115204)
    P2, N=46, Not yet recruiting, The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • lenalidomide • Inokai (orelabrutinib)
    3d
    Immuno and targeted therapy for Richter transformation to diffuse large B-cell lymphoma (ChiCTR2500109894)
    P2, N=34, Not yet recruiting, The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • PD-1 (Programmed cell death 1)
    |
    CD20 positive
    |
    lenalidomide • Tevimbra (tislelizumab-jsgr) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Columvi (glofitamab-gxbm)
    4d
    Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies (clinicaltrials.gov)
    P1, N=26, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: May 2026 --> Dec 2025
    Trial completion • Trial completion date
    |
    TNFRSF8 positive
    |
    lenalidomide • dexamethasone • Istodax (romidepsin) • Onureg (azacitidine oral)
    5d
    Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL) (clinicaltrials.gov)
    P1, N=25, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Nov 2026 --> Jan 2026 | Trial primary completion date: Nov 2026 --> Jan 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide
    5d
    A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (clinicaltrials.gov)
    P3, N=292, Recruiting, Sinocelltech Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • bortezomib • dexamethasone
    5d
    Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma (clinicaltrials.gov)
    P2, N=50, Completed, Mayo Clinic | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Mar 2025
    Trial completion • Trial completion date
    |
    lenalidomide • Darzalex (daratumumab)
    7d
    Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL) (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Nov 2025 --> Jun 2026 | Trial primary completion date: Nov 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • lenalidomide
    7d
    A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (clinicaltrials.gov)
    P2/3, N=660, Recruiting, AbbVie | Trial primary completion date: Oct 2041 --> Jan 2042
    Trial primary completion date • Adverse events
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • etentamig intravenous (ABBV-383 IV)